The announcement of a U.S. Patent approval, especially for a core technology like the orbiting blood oxygenation delivery system in the INSPIRA ART500 device, is a significant positive development for Inspira Technologies. It not only validates the company's technology but also potentially opens up new market opportunities and enhances its competitive edge. Such milestones typically result in increased investor confidence and can drive the stock price up in the short term.